53 related articles for article (PubMed ID: 26191270)
1. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK
Cancer; 2017 May; 123(6):977-984. PubMed ID: 28263384
[TBL] [Abstract][Full Text] [Related]
2. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.
Zhang M; He Y; Sun X; Li Q; Wang W; Zhao A; Di W
J Ovarian Res; 2014 Feb; 7():19. PubMed ID: 24507759
[TBL] [Abstract][Full Text] [Related]
3. SSRI use and clinical outcomes in epithelial ovarian cancer.
Christensen DK; Armaiz-Pena GN; Ramirez E; Matsuo K; Zimmerman B; Zand B; Shinn E; Goodheart MJ; Bender D; Thaker PH; Ahmed A; Penedo FJ; DeGeest K; Mendez L; Domann F; Sood AK; Lutgendorf SK
Oncotarget; 2016 May; 7(22):33179-91. PubMed ID: 27121207
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients.
Cunnea P; Gorgy T; Petkos K; Gowers SAN; Lu H; Morera C; Wu W; Lawton P; Nixon K; Leong CL; Sorbi F; Domenici L; Paterson A; Curry E; Gabra H; Boutelle MG; Drakakis EM; Fotopoulou C
Sci Rep; 2018 Oct; 8(1):14695. PubMed ID: 30279418
[TBL] [Abstract][Full Text] [Related]
5. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
6. The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response.
Bradbury A; Zenke FT; Curtin NJ; Drew Y
Cells; 2022 Aug; 11(15):. PubMed ID: 35954206
[TBL] [Abstract][Full Text] [Related]
7. H2AX mRNA expression reflects DNA repair, cell proliferation, metastasis, and worse survival in breast cancer.
Katsuta E; Sawant Dessai A; Ebos JM; Yan L; Ouchi T; Takabe K
Am J Cancer Res; 2022; 12(2):793-804. PubMed ID: 35261802
[TBL] [Abstract][Full Text] [Related]
8. Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.
Liu S; Wu M; Wang F
J Cancer; 2021; 12(13):3976-3996. PubMed ID: 34093804
[TBL] [Abstract][Full Text] [Related]
9. H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival.
Saravi S; Katsuta E; Jeyaneethi J; Amin HA; Kaspar M; Takabe K; Pados G; Drenos F; Hall M; Karteris E
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32887437
[No Abstract] [Full Text] [Related]
10. γ-H2AX as a potential indicator of radiosensitivity in colorectal cancer cells.
Kawashima S; Kawaguchi N; Taniguchi K; Tashiro K; Komura K; Tanaka T; Inomata Y; Imai Y; Tanaka R; Yamamoto M; Inoue Y; Lee SW; Kawai M; Tanaka K; Okuda J; Uchiyama K
Oncol Lett; 2020 Sep; 20(3):2331-2337. PubMed ID: 32782550
[TBL] [Abstract][Full Text] [Related]
11. Six-mRNA risk score system and nomogram constructed for patients with ovarian cancer.
Wang Q; Lu Z; Ma J; Zhang Q; Wang N; Qian L; Zhang J; Chen C; Lu B
Oncol Lett; 2019 Aug; 18(2):1235-1245. PubMed ID: 31423184
[TBL] [Abstract][Full Text] [Related]
12. Expression of p16 and p21 in the frontal association cortex of ALS/MND brains suggests neuronal cell cycle dysregulation and astrocyte senescence in early stages of the disease.
Vazquez-Villaseñor I; Garwood CJ; Heath PR; Simpson JE; Ince PG; Wharton SB
Neuropathol Appl Neurobiol; 2020 Feb; 46(2):171-185. PubMed ID: 31077599
[TBL] [Abstract][Full Text] [Related]
13. miR‑328‑3p enhances the radiosensitivity of osteosarcoma and regulates apoptosis and cell viability via H2AX.
Yang Z; Wa QD; Lu C; Pan W; Lu ZΜ; Ao J
Oncol Rep; 2018 Feb; 39(2):545-553. PubMed ID: 29207178
[TBL] [Abstract][Full Text] [Related]
14. Phospho-histone H2AX is a diagnostic and prognostic marker for epithelial ovarian cancer.
Mei L; Hu Q; Peng J; Ruan J; Zou J; Huang Q; Liu S; Wang H
Int J Clin Exp Pathol; 2015; 8(5):5597-602. PubMed ID: 26191270
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
16. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
17. Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival.
Ma R; Tang Z; Sun K; Ye X; Cheng H; Chang X; Cui H
Pathol Res Pract; 2018 Aug; 214(8):1115-1122. PubMed ID: 29921495
[TBL] [Abstract][Full Text] [Related]
18. Specific immunotherapy in ovarian cancer: a systematic review.
Aalipour S; Zoghi S; Khalili N; Hirbod-Mobarakeh A; Emens LA; Rezaei N
Immunotherapy; 2016 Oct; 8(10):1193-204. PubMed ID: 27605068
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy.
Zagouri F; Dimopoulos MA; Bournakis E; Papadimitriou CA
Eur J Gynaecol Oncol; 2010; 31(3):268-77. PubMed ID: 21077467
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
